{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:22:49Z","timestamp":1787746969790,"version":"build-2784847793"},"posted":{"date-parts":[[2026,2,17]]},"group-title":"In Review","reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,5]]},"abstract":"<title>Abstract<\/title>\n                <p>Progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is driven by coordinated metabolic reprogramming within clonal plasma cells and the bone marrow microenvironment. We applied high-resolution MALDI\u2013FT-ICR mass spectrometry imaging (MSI) to archived FFPE bone-marrow biopsies, integrated with matched bone marrow plasma metabolomics, to map spatial and systemic metabolic alterations. Spatial clustering delineated plasma-cell\u2013rich niches, while Hill-based diversity and \u03b2-diversity metrics quantified intra- and inter-compartment heterogeneity. MM niches exhibited elevated 3-hydroxykynurenine, rewired tryptophan\u2013kynurenine flux, and increased nucleotide and bioactive lipid metabolism associated with proliferation. Notably, some MGUS-like samples displayed MM-like metabolic niches undetectable in bone marrow plasma alone, underscoring spatial heterogeneity. Cross-compartment integration revealed conserved metabolic signatures and systemic redistribution of key metabolites, consistent with ecological reorganization and niche divergence during progression. These findings establish spatial metabolomics of biopsies as a framework to dissect intramedullary metabolic heterogeneity and enable metabolite-based risk stratification in plasma-cell disorders.<\/p>","DOI":"10.21203\/rs.3.rs-8795835\/v1","type":"posted-content","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:46:52Z","timestamp":1771328812000},"source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Heterogeneity and Niche Rewiring in Plasma Cells are Associated with Progression from MGUS to Multiple Myeloma"],"prefix":"10.21203","author":[{"given":"Axel","family":"Walch","sequence":"first","affiliation":[{"name":"helmholtz zentrum m\u00fcnchen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxing","family":"Zhang","sequence":"additional","affiliation":[{"name":"helmholtz zentrum m\u00fcnchen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Sun","sequence":"additional","affiliation":[{"name":"helmholtz zentrum m&#x00FC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6679-518X","authenticated-orcid":false,"given":"Yogesh","family":"Chawla","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitosugi","family":"Taro","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","author":"Dimopoulos MA","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol, (2025). https:\/\/doi.org\/10.1038\/s41571-025-01041-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-023-01472-y","article-title":"A gene signature can predict risk of MGUS progressing to multiple myeloma","volume":"16","author":"Sun F","year":"2023","unstructured":"Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, et al. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol 16, 70 (2023). https:\/\/doi.org\/10.1186\/s13045-023-01472-y.","journal-title":"J Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Donk N","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet 397, 410\u201327 (2021). https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5.","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-024-01600-2","article-title":"Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution","volume":"17","author":"Zhang F","year":"2024","unstructured":"Zhang F, Ma Y, Li D, Wei J, Chen K, Zhang E, et al. Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution. J Hematol Oncol 17, 80 (2024). https:\/\/doi.org\/10.1186\/s13045-024-01600-2.","journal-title":"J Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-024-01954-6","article-title":"Metabolic regulation of the immune system in health and diseases: mechanisms and interventions","volume":"9","author":"Hu T","year":"2024","unstructured":"Hu T, Liu CH, Lei M, Zeng Q, Li L, Tang H, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduct Target Ther 9, 268 (2024). https:\/\/doi.org\/10.1038\/s41392-024-01954-6.","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger E","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer 5, 1267\u201384 (2024). https:\/\/doi.org\/10.1038\/s43018-024-00784-3.","journal-title":"Nat Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12943-024-02113-9","article-title":"Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective","volume":"23","author":"Xiao Y","year":"2024","unstructured":"Xiao Y, Li Y, Zhao H. Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective. Mol Cancer 23, 202 (2024). https:\/\/doi.org\/10.1186\/s12943-024-02113-9.","journal-title":"Mol Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-024-01596-9","article-title":"Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications","volume":"17","author":"Liu X","year":"2024","unstructured":"Liu X, Peng T, Xu M, Lin S, Hu B, Chu T, et al. Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications. J Hematol Oncol 17, 72 (2024). https:\/\/doi.org\/10.1186\/s13045-024-01596-9.","journal-title":"J Hematol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-025-01699-x","article-title":"Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease","volume":"18","author":"Desantis V","year":"2025","unstructured":"Desantis V, Andriano A, D\u00fcking T, Hartwig O, Ingravallo G, Biondo M, et al. Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease. J Hematol Oncol 18, 47 (2025). https:\/\/doi.org\/10.1186\/s13045-025-01699-x.","journal-title":"J Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-025-08710-y","article-title":"Towards multimodal foundation models in molecular cell biology","volume":"640","author":"Cui H","year":"2025","unstructured":"Cui H, Tejada-Lapuerta A, Brbi\u0107 M, Saez-Rodriguez J, Cristea S, Goodarzi H, et al. Towards multimodal foundation models in molecular cell biology. Nature 640, 623\u201333 (2025). https:\/\/doi.org\/10.1038\/s41586-025-08710-y.","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1038\/s41598-020-67105-3","article-title":"Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma","volume":"10","author":"Gonsalves WI","year":"2020","unstructured":"Gonsalves WI, Broniowska K, Jessen E, Petterson XM, Bush AG, Gransee J, et al. Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. Sci Rep 10, 10250 (2020). https:\/\/doi.org\/10.1038\/s41598-020-67105-3.","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41375-019-0558-x","article-title":"Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma","volume":"34","author":"Ray A","year":"2020","unstructured":"Ray A, Song Y, Du T, Tai YT, Chauhan D, Anderson KC. Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. Leukemia 34, 567\u201377 (2020). https:\/\/doi.org\/10.1038\/s41375-019-0558-x.","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1038\/bcj.2015.85","article-title":"Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma","volume":"5","author":"Ludwig C","year":"2015","unstructured":"Ludwig C, Williams DS, Bartlett DB, Essex SJ, McNee G, Allwood JW, et al. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. Blood Cancer J 5, e359 (2015). https:\/\/doi.org\/10.1038\/bcj.2015.85.","journal-title":"Blood Cancer J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"108413","DOI":"10.1016\/j.compbiomed.2024.108413","article-title":"Symptom-based drug prediction of lifestyle-related chronic diseases using unsupervised machine learning techniques","volume":"174","author":"Bhattacharjee S","year":"2024","unstructured":"Bhattacharjee S, Saha B, Saha S. Symptom-based drug prediction of lifestyle-related chronic diseases using unsupervised machine learning techniques. Comput Biol Med 174, 108413 (2024). https:\/\/doi.org\/10.1016\/j.compbiomed.2024.108413.","journal-title":"Comput Biol Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"216924","DOI":"10.1016\/j.canlet.2024.216924","article-title":"Tuning cellular metabolism for cancer virotherapy","volume":"592","author":"Xiong D","year":"2024","unstructured":"Xiong D, Wang Q, Wang WM, Sun ZJ. Tuning cellular metabolism for cancer virotherapy. Cancer Lett 592, 216924 (2024). https:\/\/doi.org\/10.1016\/j.canlet.2024.216924.","journal-title":"Cancer Lett"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/15548627.2023.2247310","article-title":"Autophagy preserves hematopoietic stem cells by restraining MTORC1-mediated cellular anabolism","volume":"20","author":"Borsa M","year":"2024","unstructured":"Borsa M, Obba S, Richter FC, Zhang H, Riffelmacher T, Carrelha J, et al. Autophagy preserves hematopoietic stem cells by restraining MTORC1-mediated cellular anabolism. Autophagy 20, 45\u201357 (2024). https:\/\/doi.org\/10.1080\/15548627.2023.2247310.","journal-title":"Autophagy"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/hon.3108","article-title":"Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients","volume":"41","author":"Asano A","year":"2023","unstructured":"Asano A, Ri M, Masaki A, Maeda Y, Tachita T, Hirade K, et al. Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients. Hematol Oncol 41, 424\u201333 (2023). https:\/\/doi.org\/10.1002\/hon.3108.","journal-title":"Hematol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1158\/1078-0432.Ccr-24-2000","article-title":"Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma","volume":"31","author":"Morelli E","year":"2025","unstructured":"Morelli E, Ribeiro CF, Rodrigues SD, Gao C, Socciarelli F, Maisano D, et al. Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. Clin Cancer Res 31, 1975\u201387 (2025). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-2000.","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-025-01232-w","article-title":"Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma","volume":"15","author":"Zanwar S","year":"2025","unstructured":"Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, et al. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma. Blood Cancer J 15, 20 (2025). https:\/\/doi.org\/10.1038\/s41408-025-01232-w.","journal-title":"Blood Cancer J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1080\/15548627.2023.2208931","article-title":"Blocking glycosphingolipid production alters autophagy in osteoclasts and improves myeloma bone disease","volume":"20","author":"Leng H","year":"2024","unstructured":"Leng H, Simon AK, Horwood NJ. Blocking glycosphingolipid production alters autophagy in osteoclasts and improves myeloma bone disease. Autophagy 20, 930\u20132 (2024). https:\/\/doi.org\/10.1080\/15548627.2023.2208931.","journal-title":"Autophagy"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.1038\/s41467-022-35358-3","article-title":"Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease","volume":"13","author":"Leng H","year":"2022","unstructured":"Leng H, Zhang H, Li L, Zhang S, Wang Y, Chavda SJ, et al. Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease. Nat Commun 13, 7868 (2022). https:\/\/doi.org\/10.1038\/s41467-022-35358-3.","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.05.011","author":"Tran DH","year":"2024","unstructured":"Tran DH, Kim D, Kesavan R, Brown H, Dey T, Soflaee MH, et al. De novo and salvage purine synthesis pathways across tissues and tumors. Cell 187, 3602-18.e20 (2024). https:\/\/doi.org\/10.1016\/j.cell.2024.05.011."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","article-title":"Nucleotide metabolism: a pan-cancer metabolic dependency","volume":"23","author":"Mullen NJ","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer 23, 275\u201394 (2023). https:\/\/doi.org\/10.1038\/s41568-023-00557-7.","journal-title":"Nat Rev Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02071-z","author":"Pfeiffer C","year":"2024","unstructured":"Pfeiffer C, Grandits AM, Asnagli H, Schneller A, Huber J, Zojer N, et al. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1. Leukemia 38, 181\u2009\u2013\u200992 (2024). https:\/\/doi.org\/10.1038\/s41375-023-02071-z."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood.2024025690","article-title":"Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis","volume":"145","author":"Nair R","year":"2025","unstructured":"Nair R, Vu AH, Freer AK, Bhatia KS, Wang D, Savani MR, et al. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood 145, 732\u201347 (2025). https:\/\/doi.org\/10.1182\/blood.2024025690.","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","article-title":"Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma","volume":"11","author":"Oudaert I","year":"2022","unstructured":"Oudaert I, Van der Vreken A, Maes A, De Bruyne E, De Veirman K, Vanderkerken K, et al. Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma. Exp Hematol Oncol 11, 49 (2022). https:\/\/doi.org\/10.1186\/s40164-022-00303-z.","journal-title":"Exp Hematol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni C","year":"2022","unstructured":"Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood 139, 876\u201388 (2022). https:\/\/doi.org\/10.1182\/blood.2021013832.","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027496","article-title":"Reprogramming glutamine metabolism enhances BCMA-CART cell fitness and therapeutic efficacy in multiple myeloma","author":"Navarro F","year":"2025","unstructured":"Navarro F, Lozano T, Fuentes-Garc\u00eda A, S\u00e1nchez-Moreno I, Larrayoz M, Justicia P, et al. Reprogramming glutamine metabolism enhances BCMA-CART cell fitness and therapeutic efficacy in multiple myeloma. Blood, (2025). https:\/\/doi.org\/10.1182\/blood.2024027496.","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1182\/blood.2024026227","article-title":"Immune alterations in myeloma evolution and outcomes: quo vadis? Blood 146","author":"Dhodapkar MV","year":"2025","unstructured":"Dhodapkar MV, Paiva B. Immune alterations in myeloma evolution and outcomes: quo vadis? Blood 146, 1041\u201350 (2025). https:\/\/doi.org\/10.1182\/blood.2024026227."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40364-023-00502-8","article-title":"Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications","volume":"11","author":"Chen M","year":"2023","unstructured":"Chen M, Jiang J, Hou J. Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications. Biomark Res 11, 55 (2023). https:\/\/doi.org\/10.1186\/s40364-023-00502-8.","journal-title":"Biomark Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","article-title":"Modulation of T cells by tryptophan metabolites in the kynurenine pathway","volume":"44","author":"Stone TW","year":"2023","unstructured":"Stone TW, Williams RO. Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci 44, 442\u201356 (2023). https:\/\/doi.org\/10.1016\/j.tips.2023.04.006.","journal-title":"Trends Pharmacol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153764","article-title":"Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures","volume":"15","author":"Dunphy K","year":"2023","unstructured":"Dunphy K, Bazou D, Henry M, Meleady P, Miettinen JJ, Heckman CA, et al. Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures. Cancers (Basel) 15, (2023). https:\/\/doi.org\/10.3390\/cancers15153764.","journal-title":"Cancers (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.08.006","article-title":"Global Analysis of Plasma Lipids Identifies Liver-Derived Acylcarnitines as a Fuel Source for Brown Fat Thermogenesis","volume":"26","author":"Simcox J","year":"2017","unstructured":"Simcox J, Geoghegan G, Maschek JA, Bensard CL, Pasquali M, Miao R, et al. Global Analysis of Plasma Lipids Identifies Liver-Derived Acylcarnitines as a Fuel Source for Brown Fat Thermogenesis. Cell Metab 26, 509\u2009\u2013\u200922.e6 (2017). https:\/\/doi.org\/10.1016\/j.cmet.2017.08.006.","journal-title":"Cell Metab"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/jcsm.12817","article-title":"Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients","volume":"12","author":"Catanese S","year":"2021","unstructured":"Catanese S, Beuchel CF, Sawall T, Lordick F, Brauer R, Scholz M, et al. Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients. J Cachexia Sarcopenia Muscle 12, 2101\u201310 (2021). https:\/\/doi.org\/10.1002\/jcsm.12817.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamainternmed.2024.8124","article-title":"Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review","volume":"185","author":"Liu Y","year":"2025","unstructured":"Liu Y, Parks AL. Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review. JAMA Intern Med 185, 450\u20136 (2025). https:\/\/doi.org\/10.1001\/jamainternmed.2024.8124.","journal-title":"JAMA Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41698-023-00434-4","article-title":"Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma","volume":"7","author":"Wang J","year":"2023","unstructured":"Wang J, Sun N, Kunzke T, Shen J, Zens P, Prade VM, et al. Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma. NPJ Precis Oncol 7, 114 (2023). https:\/\/doi.org\/10.1038\/s41698-023-00434-4.","journal-title":"NPJ Precis Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.05.007","author":"Dang M","year":"2023","unstructured":"Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41, 1032-47.e4 (2023). https:\/\/doi.org\/10.1016\/j.ccell.2023.05.007."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta AK","year":"2022","unstructured":"Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol 19, 223\u201336 (2022). https:\/\/doi.org\/10.1038\/s41571-021-00593-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1172\/jci167629","article-title":"Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy","volume":"133","author":"Robinson MH","year":"2023","unstructured":"Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS, et al. Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. J Clin Invest 133, (2023). https:\/\/doi.org\/10.1172\/jci167629.","journal-title":"J Clin Invest"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8795835\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8795835\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:58:56Z","timestamp":1787745536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8795835\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":39,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8795835\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41408-026-01525-8","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,2,17]]},"subtype":"preprint"}}